Pemetrexed

Pemetrexed

SCHEMBL6034765

Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1.Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHFRGARTTYMSthyA

The experimentally established mechanism targets of Pemetrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GART known ✓ P22102 10/20 0.77
DHFR known ✓ P00374 6/20 0.77
TYMS known ✓ P04818 5/20 0.77
FOLR1 P15328 4/20 0.77
SLC46A1 Q96NT5 4/20 0.77
ATIC P31939 3/20 0.77
FOLR2 P14207 3/20 0.77
SLC19A1 P41440 3/20 0.77
SHMT1 P34896 2/20 0.77
FRK P42685 1/20 0.77
SHMT2 P34897 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pemetrexed SCHEMBL7968 1.00 GART (0.77) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL7969 1.00 GART (0.77) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL2549428 1.00 GART (0.77) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL108860 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL124673 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL3388816 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL1934793 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL126068 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL124663 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1
Pemetrexed SCHEMBL15648731 0.99 GART (0.76) GARTDHFRTYMSFOLR1SLC46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110475571-A The substitution of cytotoxicity preconditioned before cellular immunotherapy AVM BIOTECHNOLOGY LLC 2019-11-19 CN disclosed
EP-3429571-A1 COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS Oryzon Genomics, S.A. (ES) 2019-01-23 EP disclosed
WO-2017157825-A1 COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS F. HOFFMANN-LA ROCHE AG (CH) 2017-09-21 WO disclosed
EP-1711188-A2 ANTI-CANCER THERAPIES Threshold Pharmaceuticals, Inc. (US) 2006-10-18 EP disclosed
WO-2005076888-A2 ANTI-CANCER THERAPIES THRESHOLD PHARMACEUTICALS, INC. (US) 2005-08-25 WO disclosed